|Dr. Martine A. Rothblatt||Founder, Chairman & CEO||3.24M||20.56M||1955|
|Mr. Michael I. Benkowitz||Pres & COO||1.96M||1.99M||1972|
|Mr. James C. Edgemond||CFO & Treasurer||1.42M||N/A||1968|
|Mr. Paul A. Mahon||Exec. VP, Gen. Counsel & Corp. Sec.||1.67M||1.04M||1964|
|Mr. Dewey Steadman C.F.A., CFA||Head of Investor Relations||N/A||N/A||N/A|
|Ms. Holly Hobson||Associate VP of HR||N/A||N/A||N/A|
|Kevin T. Gray||Sr. VP of Strategic Operations & Logistics||N/A||N/A||N/A|
|Mr. Patrick Poisson||Exec. VP of Technical Operations||N/A||N/A||1968|
|Mr. Gil Golden||Sr. VP & Chief Medical Officer||N/A||N/A||N/A|
|Leigh Peterson||VP of Product Devel.||N/A||N/A||N/A|
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhance the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing OreniPro, RemoPro, Tyvaso DPI, Trevyent, Ralinepag, and Aurora-GT to treat PAH; Unexisome to treat bronchopulmonary dysplasia; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. It has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder and Dreamboat devices; and Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
United Therapeutics Corporation’s ISS Governance QualityScore as of July 1, 2021 is 3. The pillar scores are Audit: 5; Board: 2; Shareholder Rights: 3; Compensation: 4.